Status:
NOT_YET_RECRUITING
Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients
Lead Sponsor:
Qianfoshan Hospital
Conditions:
Flumazenil to Antagonize Remimazolam
Remimazolam
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
To investigate the effect of different doses of flumazenil antagonism on remimazolam plasma concentration in patients undergoing renal transplantation under general anesthesia.
Detailed Description
During the surgery, other anesthetics, intraoperative monitoring, fluid management, and postoperative pain management were implemented according to a unified standard. 1. Intraoperative Monitoring Al...
Eligibility Criteria
Inclusion
- Age ≥ 18 years and \< 65 years
- Patients undergoing elective kidney transplant surgery
- Signed the informed consent for the clinical study
Exclusion
- Liver decompensation (Child B/C)
- History of liver transplant
- Previous allergies or other serious adverse reactions to narcotic drugs
- Intraoperative depth monitoring of anesthesia is not expected
- Preoperative ASA rating of 5
- Received general anesthesia in the 30 days prior to surgery or plan to receive it again within 30 days
- Plan to extend airway protection or mechanical ventilation support time after surgery
- Previous participation in this study
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06531369
Start Date
July 1 2024
End Date
March 1 2026
Last Update
August 1 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.